AstraZeneca’s Andexxa Could Be Headed For Withdrawal After US FDA’s Negative Advisory Committee Preview

The confirmatory trial for the anticoagulant reversal agent raised safety and efficacy concerns from the agency.

exit painted on pavement.
A negative 21 November advisory committee recommendation could portend a marketing exit for Andexxa. (Shutterstock)

More from US Advisory Committees

More from Product Reviews